Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Thats why Im excited to share the latest research on GLP-1 receptor agonists and their potential in treating autoimmune diseases
Cardioprotective functions in heart failure Both preclinical and clinical studies have demonstrated beneficial effects of GLP-1 on the failing heart
It's an investigational drug currently in Phase 3 clinical trials Eli Lilly's TRIUMPH Phase 3 program includes multiple trials for obesity, type 2 diabetes, NASH, and cardiovascular outcomes Expected timeline: FDA submission in 2026, potential approval in 20272028 Phase 2 results showed 24.2% weight loss at 48 weeks, the highest ever recorded for a GLP-1 class medication How to access now: Clinical trial enrollment (free), compounding pharmacies (with important legal caveats), or research peptides (grey market) When approved, retatrutide will be the first triple-agonist obesity medication (GLP-1 + GIP + glucagon) Is Retatrutide FDA Approved
Why is slow gut motility linked to SIBO
US$ 26.28
US$ 21.23
US$ 29.74
US$ 25.79
US$ 28.39
